跳至主要内容
临床试验/NCT01680575
NCT01680575Unknown不适用

Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model

Asan Medical Center1 个研究点 分布在 1 个国家目标入组 750 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
750
试验地点
1
主要终点
Risk prediction model for grade 3-4 chemotherapy induced neutropenia

研究概览

简要总结

To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking surgery
  • Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin
  • Patients who have signed approved informed consent

排除标准

  • Uncontrolled medical disease
  • Active infectious disease
  • Previous pelvic radiation therapy
  • Previous chemotherapy (prospective cohort)
  • Patients with disease which can cause neutropenia
  • Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort).
  • Pregnant or lactating woman

结局指标

主要结局

Risk prediction model for grade 3-4 chemotherapy induced neutropenia

时间窗: 1 year

次要结局

  • The association between mannose-binding lectin 2 gene SNP and neutropenia(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeong-Yeol Park

Clinical Assistant Professor

Asan Medical Center

研究点 (1)

Loading locations...

相似试验